Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04301414 · ClinicalTrials.gov registry record · Early Phase 1
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
A Early Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT04301414 is a Early Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 26 participants.
The verdict
NCT04301414, a Early Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses testosterone) given prior to surgery can decrease the chance that cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not receive any additional therapy prior to surgery. Approximately 24 individuals will be asked to participate in this study.
Interventions
- DRUG Degarelix
- DRUG BMS-986218 and Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2025-03-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04301414
The ClinicalTrials.gov registry entry for NCT04301414 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT04301414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04301414 about?
NCT04301414 is a clinical study titled "Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer". The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses testosterone) given prior to surgery can decrease the chance that cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not rece...
What is the current status of trial NCT04301414?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2020-02-25. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT04301414?
The interventions under investigation include: Degarelix (DRUG), BMS-986218 and Degarelix (DRUG).
Who is sponsoring clinical trial NCT04301414?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.